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Abstract: Ca
2+-regulated photoproteins of luminous marine coelenterates are of interest 
and a challenge for researchers as a unique bioluminescent system and as a promising 
analytical instrument for both in vivo and in vitro applications. The proteins are 
comprehensively studied as to biochemical properties, tertiary structures, bioluminescence 
mechanism, etc. This knowledge, along with available recombinant proteins serves the 
basis for development of unique bioluminescent detection systems that are   
“self-contained”, triggerable, fast, highly sensitive, and non-hazardous. In the paper, we 
focus on the use of photoproteins as reporters in binding assays based on immunological 
recognition element—bioluminescent immunoassay and hybridization immunoassay, their 
advantages and prospects. 
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1. Introduction 
Ca
2+-regulated photoproteins of luminous marine coelenterates [1] are stable complexes of 
apophotoprotein (a single-chain polypeptide with molecular mass around 20 kDa) and a pre-oxidized 
substrate molecule—peroxycoelenterazine—which is strongly but non-covalently immobilized in the 
protein hydrophobic cavity [2,3]. The primary structures of photoproteins known today reveal high 
homology and all have three Ca
2+-binding sites [4]. Upon Ca
2+ addition, proteins undergo 
conformational changes that cause substrate decarboxylation resulting in the protein bound   
product—coelenteramide—in an excited state (Figure 1A). The energy of the reaction releases as a 
OPEN ACCESSSensors 2010, 10                  
 
 
11288
flash of blue light, centered at 469–495 nm, depending on the protein origin (Figure 1C). Excess of 
calcium ions induces a rapid reaction, with a decay period of activated intermediate less than 1 sec 
(Figure 1B). Bioluminescence (BL) is detected in a luminometer allowing injection of calcium solution 
and simultaneous measurement of light. The BL produced by photoproteins overlaps several logs of 
concentration with a linear relationship between protein amount (Figure 1D) and BL and high   
signal-to-background ratio. In contrast to the luciferase reaction, photoprotein bioluminescence does 
not depend on oxygen or substrate concentration. A high quantum yield of the reaction, a virtual 
absence of the background BL signal, and a high sensitivity of modern photometers make the 
photoprotein detection down to attomole level possible. 
Figure 1. Bioluminescence of Ca
2+-regulated photoprotein. (A) Scheme for the reaction: 
photoprotein is a complex of single-chain polypeptide, containing Ca
2+-binding sites (I, II, 
III) and pre-oxidized coelenterazine (CE-O2). The binding of Ca
2+ results in coelenterazine 
decarboxylation yielding a stable complex of polypeptide, three Ca
2+ and coelenteramide 
(CM), carbon dioxide and a quantum of light. (B) Kinetics of aequorin (-○-) and   
obelin (-∆-) bioluminescence signals. (C) Bioluminescence spectra of aequorin (solid line) 
and obelin (dashed line). (D) Obelin amount versus bioluminescence. 
 
To date, Ca
2+-regulated photoproteins have been discovered in more than 25 different 
coelenterates [1]. Among them, the best investigated are aequorin, named for its origin in the jellyfish 
Aequorea and obelin, from the hydroid polyp Obelia. The cDNAs of the proteins were cloned and 
expressed in a high yield in bacterial cells. Recombinant apoproteins are effectively activated with a 
synthetic coelenterazine under calcium-free conditions in the presence of O2 and reducing   
reagent [5–8]. The proteins are comprehensively studied as to biochemical and biophysical properties, 
tertiary structures, bioluminescence mechanism etc. This knowledge along with practically unlimited 
amounts of recombinant proteins serves the basis for development of unique bioluminescent detection 
system that is “self-contained”, triggerable, fast, highly sensitive, and non-hazardous. Sensors 2010, 10                  
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One of the applications of photoproteins is conditioned by their sensitivity to calcium ions in a 
physiological range of concentration where those are used as a valuable probe for studying 
intracellular Ca
2+ [9,10]. But of no less interest is the application of photoproteins (at saturating Ca
2+ 
concentrations) as effective reporters in binding assay of various biologically active substances. Here 
we focus on the use of aequorin and obelin in: (a) bioluminescent immunoassay, (b) bioluminescent 
PCR-ELISA, (c) assay in tandem with the other reporters, and on analytical application of   
re-engineered photoproteins as well. The data over last 15 years will be reviewed. 
2. Bioluminescent Immunoassay 
Publications have described the use of photoproteins as immunoassay reporters since the early 
1990s when the active recombinant proteins became available. In estimating photoproteins as labels, 
several obvious advantages of those were taken into account: practically unlimited linear range of 
bioluminescence, the lack of background, the simplicity the reaction is triggered with, the availability 
of modern registration devices and the absence of toxicity. The application of photoproteins as tracers 
in binding assays required that their tolerance to chemical modifications be ascertained—conjugation 
with the other molecules (antigens or antibodies) or binding of definite anchor groups serving as 
effective bridges between the molecules of the immune complex. Erikaku et al. [11] chemically 
conjugated apoaequorin with human necrosis factor-α (hTNF) antibodies (Fab fragment). They found 
that aequorin activity in the conjugate was regenerated (by incubation with coelenterazine) up to only 
10% of the free photoprotein activity. Nevertheless, the sensitivity of the hTNF assay (standard 
samples) was one attomole, approximately 100-fold higher than that achievable using the analogous 
conjugate with β-galactosidase. Later it was demonstrated that photoproteins (preliminary 
coelenterazine-activated apophotoproteins) are essentially more stable to chemical modifications than 
apoproteins and their active conjugates can be easily obtained applying commercially available 
reagents and cross-linkers [12–16]. The conjugates in solution as well as in frozen and lyophilized 
states were found to be stable and easily stored. Consequently, in the following years a great number of 
publications described photoprotein-based immunoassays of different analytes of clinical interest – 
hormones, interleukins, oncomarkers, etc. [12–26], and infections [26–28]. The assays were carried out 
in different formats (sandwich, competitive), and performed in solid-phase, homogeneous and even 
flow injection [29] variants. The papers considered investigations of model samples as well as sera, 
saliva, mucous of patients and experimental animals. 
Of special interest are the evaluations of the aequorin-based thyrotropin (TSH) assay undertaken at 
the Pathology and Laboratory Medicine Departments of Emory University and the Veterans 
Administration Hospital (Atlanta, USA) [20]. The authors measured serum TSH in 153 euthyroid 
individuals with thyroidal illnesses (primary hypo- and hyperthyroids, thyroids cancer, etc.) applying 
bioluminescent methods (developed and marketed by SeaLite Inc., USA) and compared the results 
with the data obtained by commercially available Nichols, ACS-180 and TOSOH methods. They 
found that aequorin-based method has the required performance characteristics (e.g., the functional 
sensitivity of 0.017 mIU/L, which is higher than in the cases of ACS-180 and TOSOH assays) and is 
“clearly qualified as a last, third-generation TSH assay”. In [19], reproducibility of bioluminescent 
immunoassay of TSH and thyroxin in sera of patients, treated by different medicines (more than Sensors 2010, 10                  
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20 items) was investigated. No significant influence of substances or their metabolites on the assay 
results was observed, this pointing to the high reliability of the assay. 
The unique bioluminescence nature of photoproteins (triggering with Сa
2+, flash-type signal) 
conditioned their application in tandem with other reporters to provide simultaneous detection of 
several antigens in one sample. The tandem luminescence concept was demonstrated by   
Adamczyk et al. [30] who applied aequorin and acridinium-9-carboxamide labels in a model assay 
system. The signals were triggered sequentially by injection of Ca
2+ solution followed by basic 
peroxide, with a total read time of 20 s. It was concluded that the relatively short assay time and the 
well-resolved signals made this format suitable for the development of dual analyte high-throughput 
assays. Ito and co-authors [31] developed highly sensitive and rapid immunoassay of two antigens 
involving aequorin and firefly luciferase labels. The authors detected two couples of   
antigens—prostatic acid phosphatase (PAP) with prostate specific antigen (PSA) (measurable ranges 
of 0.04–100 and 0.2–200 ng/mL, respectively) and PSA with alphafetoprotein (AFP) (measurable 
ranges of 0.2–200 and 1.95–1000  ng/mL, respectively). Figure 2 illustrates the proposed tandem 
immunoassay. With the developed technique applied, PAP, PSA and AFP were detected in standard 
and then in clinical sera. The values obtained from the developed simultaneous assay were in good 
correlation with those derived from conventional methods. Worthy of notice is the approach further 
developed for multiplex hybridization assay with aequorin used in tandem with several reporters (see 
e.g., [50]). 
Figure 2. Generalized scheme for dual bioluminescent immunoassay using aequorin in 
tandem with firefly luciferase, according to [31]. The surface was activated by antibodies 
of two types (1) against two antigens (2). Secondary antibodies (3) were tagged with 
digoxigenin and biotin. The sandwiches, formed on the surface were detected using 
conjugate aequorin-antidigoxigenin Fab fragment and biotinylated luciferase-streptavidin 
complex (4). Ca
2+ injection triggered flash-type aequorin bioluminescence and then the 
mixture of luciferin, ATP and Mg
2+ was placed into the wells to initiate luciferase 
bioluminescence. 
 
 
The data considered above obviously testify to the high level of research on photoprotein-based 
immunoassay. Actually, the state-of-the-art in the field allows wide-scale introducing bioluminescent 
analytical technologies into practical use under clinical conditions. Sensors 2010, 10                  
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3. Bioluminescent Immunoassay for PCR Products Quantitation 
The polymerase chain reaction (PCR) has proved to be of great value in diagnostic research. Its 
ability to amplify specific nucleic acid sequences several million-fold as much has facilitated detection 
of a small number of DNA copies. For some diagnosis it is necessary to establish the presence or 
absence of the sequence of interest (diseases associated with infectious agents, gene deletions, SNP, 
etc.). In some cases quantitative PCR analysis is important in order to evaluate therapy effectiveness, 
detect gene expression through reverse transcriptase-polymerase chain reaction (RT-PCR), etc. The 
traditional approach of PCR products calculation was (and is sometimes!) their visualization after 
separation on agarose gel by DNA bands density, or scintillation counting of radiolabeled products. 
The obvious shortcomings of these techniques—low sensitivity, bulkiness to perform or the need to 
use radioactive materials—have hampered implementation of these assays in routine settings. That is 
why new non-radioisotope methods allowing quantification of PCR products are being intensively 
developed. 
In this respect some features are to be taken into account. Firstly, determination of the original 
number of copies requires a constant relationship between the product yield and the input molecules. 
But as the number of cycle increases the amplification process diverges from an exponential product 
generation and reaches a plateau, so quantitative analysis must be restricted to the exponential phase of 
the reaction. At the same time, the smaller number of cycles results in decrease of the product amount 
to be analyzed, so the detection sensitivity should be extremely high. Secondly, despite the use of high 
temperatures, non-specific primer annealing may occur during PCR, and errors are exponentially 
amplified through multiple cycles. In order to discriminate these products and to obtain a higher level 
of specificity, a hybridization step must be included into assays. And thirdly, attention should be paid 
to the dynamic range of instruments used for quantitative measurements. 
One of the approaches meeting all the demands is the PCR-ELISA method, proposed by   
Vlieger et al. in 1992 [32]. The merit of the method lies in the combination of PCR, oligonucleotide-
hybridization and enzyme immunoassay capabilities. In general the assay includes three steps 
(Figure 3): PCR is carried out using specifically-labeled forward primer and amplicons (labeled strand) 
are immobilized on a surface (covalently or by affinity coupling); hybridization with tagged probe; 
immuno-enzymatic “recognition” and evaluation of probe-DNA duplexes. In some cases tagged probe 
is added to the mixture after amplification and hybridization is performed using temperature 
denaturation of amplicons. Then hybrids carrying two different labels are immobilized on the surface. 
The same technique is applicable to analyze small amounts of mRNA via reverse   
transcriptase-polymerase chain reaction (RT-PCR) followed by ELISA [33]. Since the early 90ies 
several modifications of the method have been developed, based on colorimetric, fluorescent and 
chemiluminescent detection [34,35], mostly in microplate format. 
In 1996 Siddiqi et al. proposed the use of the photoprotein aequorin as a bioluminescent 
reporter  [36]. The aequorin-based assay of IL-2 PCR product was compared to 
electrochemiluminescence-based (ECL) assay. It was found that BL assay detected down to 
1 × 10
13 copies (14 cycles), while ELC—1.5 × 10
14 copies (18 cycles). The detection rate for ECL is 
48 samples/h, and for aequorin-based microplate assay—one sample/3 second, so the BL assay turned 
out to be more rapid, sensitive and inexpensive than ECL. Sensors 2010, 10                  
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Figure 3. Scheme for PCR-ELISA method developed by Vlieger et al. [30]. 1. amplicon 
labeled strands immobilization on the surface; 2. hybridization with tagged probe;   
3. immuno-enzymatic complex formation; 4. amplicon detection through enzyme reaction. 
 
 
In the same year Xiao et al. [37] applied an aequorin-based immunoassay for quantitation of   
RT-PCR amplified cytokine mRNA. The cDNA was synthesized from total mRNA isolated from 
stimulated murine splenocytes, and amplified for IL-2, IL-4, IL-10 and IFN-γ. The technique enabled 
detection of as low as 40 amol of amplified cytokine products or 500 copies of templates using 
28  cycles. This detection level is essentially lower than that of the colorimetry-based enzymatic 
immunoassay level (fmol). Besides, the BL-based assay has an essentially higher dynamic range and 
smaller coefficient of variation, especially for small amounts of product (less than 5% versus 20%). 
Similar investigations were carried out by Actor et al. [38]. They detected RT-PCR amplified mRNA 
for 10 cytokines in stimulated and unstimulated human cells using aequorin-based technology. The 
significant advantages of bioluminescent method as opposed to the radioactive one were revealed, i.e., 
higher sensitivity and ability to analyze products in an automated microtiter plate format. Shortly after 
that, bioluminescent immunoassay in combination with internal standard and competitive 
coamplification technique [39] was demonstrated as an accurate tool for DNA and mRNA quantitation 
in many medico-biological applications: to quantify human immunodeficiency virus (HIV-1) DNA or 
RNA in plasma, vaginal lavage and cultured cells [40]; to evaluate efficacy of conventional and DNA 
vaccinations against Helicobacter pylory [41]; and to investigate gene expression under infectious 
disease conditions [42–46].  
Within the framework of the review we focus only on the methods using immunological recognition 
elements but not less interesting and prospective are the techniques involving aequorin-biotin   
(or -streptavidin) or aequorin-oligonucleotide conjugates [47–50]. 
4. Analytical Application of Re-Engineered Photoproteins 
Re-engineered (genetically modified) photoproteins have been widely described in literature. Part of 
them were obtained in the course of fundamental studies on elucidation of the role of some amino 
acids in bioluminescent reactions, other ones—in applied studies aimed at the creation of   Sensors 2010, 10                  
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photo-proteins with novel useful properties (altered bioluminescence spectrum and kinetics, Ca
2+-
sensitivity, etc.). Of course, this boundary is far from being strict and in reality fundamental and 
applied investigations interact and are complementary. 
Attempts to vary the bioluminescence of photoproteins (to alter their spectral characteristics, 
kinetics, Ca
2+-sensitivity,  etc.) using site-directed mutagenesis have been undertaken since their 
cDNAs were cloned. The W86→F86 substitution in the aequorin molecule, for instance, was found to 
give an additional violet band in the bioluminescence spectrum, with a violet-to-blue ratio of 0.4 [51]. 
The  corresponding W92→F92 substitution in  the  obelin molecule gives the same effect with a   
violet-to-blue ratio of 1 [52]. This spectrum changes take place because the reaction product—excited 
state coelenteramide—can form several kinds of light emitters, depending on the surroundings [53]. 
Thus, the site-directed replacement of amino acids in coelenterazine-binding pocket that changes its 
polarity and hydrogen-bond network can result in the formation of different emitters. 
Rationally directed re-engineering of photoproteins came into being in 2000, when the spatial 
structures of aequorin and obelin were solved [2,3] and as a consequence, the amino acids essential for 
the bioluminescence reaction were proposed. In the case of obelin it was found that mutagenesis of 
W92, W179, H22, H175, Y138, and Y190 residues changes the bioluminescence activity and (or) 
spectrum [54–56]. Some of the mutants had high bioluminescence activity and stability, thus allowing 
their use as reporters. The “violet” W92F, H22E and “greenish” Y138F obelins were applied in a one-
stage dual-color simultaneous immunoassay of two gonadotropic hormones—follicle-stimulating 
hormone (FSH) and luteinizing hormone (LH) in one serum sample [56]. Bioluminescence of the 
reporters was simultaneously triggered by a single injection of Ca
2+ solution, divided using band-pass 
optical filters and measured with a two-channel photometer (Figure 4). The sensitivity of the 
simultaneous bioluminescence assay was close to that of a separate radioimmunoassay. 
To design aequorin with unique bioluminescent properties two strategies were applied: site-directed 
mutagenesis and incorporation of coelenterazine analogues that retained bioluminescence activity with 
a concomitant spectrum shift [57,58]. In a recent publication, the use of coelenterazine analogues was 
combined with site-directed incorporation of non-natural amino acids to modulate spectrum 
emission  [59]. It should be noted however that all these aequorins with altered bioluminescence 
displayed shifted, but rather wide signals, with essential overlapping areas, that makes signal 
discrimination rather difficult. Simultaneous, dual-analyte immunoassay for 6-keto-prostaglandin-FI-
alpha and angiotensin II, two important cardiovascular molecules, was successfully realized in [60]. In 
this particular case the signals of both aequorin variants were triggered by Ca
2+ and resolved from one 
another using the differences in decay kinetics. 
Multi-analyte approach allows intensification of the assay procedure especially in the case when, 
for proper diagnostics, it is recommended to detect several analytes in one sample. Simultaneous 
determination may be useful for large-scale investigation and may offer advantages in terms of cost 
and labor savings. 
One more type of re-engineered variants is a photoprotein genetically fused with the proteins of 
interest. The gene-fusing technique has become an increasingly useful tool in biomedical research. For 
instance, the construction of bifunctional molecules containing bio-specific and reporter modules 
provides effective markers to be applied in both in vivo and in vitro assays. The main advantages of the 
labels obtained as fused proteins are: (1) the lack of bulky chemical crosslinking stages, (2) high Sensors 2010, 10                  
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activity of enzyme module, not subjected to any chemical treatments and (3) usually simple way to 
purify chimeric proteins with affinity chromatography. 
Figure 4. Color photoprotein obelin mutants as reporters in dual immunoassay according 
to [56]. (A) Bioluminescence spectrum of “violet” (W92F, H22E) and “greenish” 
(Y138F) obelin mutants (thick lines); band-pass optical filters I and II transmission (thin 
lines). (B) Simultaneous dual-color bioluminescence immunoassay of LH and FSH: the 
surface was activated with anti-α-FSH (the same for both hormones) IgG. Sandwich 
immunocomplex formed at incubation of hormones and conjugates of obelin mutants with 
corresponding hormones anti-β-subunits (specific for every hormone) IgGs mixture. 
Reporters’ bioluminescence was simultaneously triggered by single injection of Ca
2+ 
solution, divided using band-pass optical filters and measured with a two-channel 
photometer. 
 
 
The Ca
2+-regulated photoproteins hold much promise as reporter modules providing high sensitivity 
to the assays under development. It is not surprising that one of the first bioluminescent immunoassays 
was proposed on the basis of aequorin genetically fused with immunoglobulin heavy-chain [61]. 
Antibody-aequorin chimera was expressed in mammalian cells and possessed photoprotein 
bioluminescent activity, close to that of WT aequorin and high antibody binding ability and was used 
as an immunoassay label. Photoproteins fused with Staphylococcus aureus protein A or its 
immunoglobulin-binding fragment Z are universal labels for IgG detection [62,63]. Photoproteins 
fused with biotin-acceptor peptide, are biotinylated post-translationally and can be utilized as reporter 
molecules in assays based on avidin-biotin technology [64,65]. It was established that aequorin being 
fused with biologically active polypeptides, “works” successfully as an N-terminal or C-terminal 
partner [66,67]. Thus the photoprotein module has proved to be a sensitive reporter applicable for 
obtaining fusion proteins and the further development of such constructions depends on availability of 
corresponding selective recognition elements. 
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5. Conclusions  
The Ca
2+-regulated photoproteins of luminous marine coelenterates were discovered at the 
beginning of the 60ies and have been of interest and challenge for researchers as a unique 
bioluminescent system and as a promising analytical instrument ever since. The availability of 
recombinant proteins has stimulated the studies on their applications as supersensitive tracers in 
bioluminescent binding assays. Convincingly good experimental results, commercial availability of 
photoproteins and their conjugates as well as of various photometers of high sensitivity allow   
wide-scale introduction of bioluminescent analytical technologies into practical use in medicine and 
biotechnology. This review is concerned only with immunoassay technologies, but the spectrum of 
applications of photoproteins as supersensitive analytical tools is essentially broader and the number of 
papers on the topic is enormous. More information can be found elsewhere [68–70].  
No doubt, bioluminescence assays based on Ca
2+-regulated photoproteins look highly promising 
from the standpoint of increasing demands of modern science. The main directions here are the 
creation of multianalytical systems, assay miniaturization, and the development of high-throughput 
technologies and sensors. 
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